We assessed the diagnostic usefulness of adding anti-CD117 to our existing flow cytometric profile in the analysis of 150 consecutive cases of acute leukemia (de novo CD117 (c-kit) is a transmembrane tyrosine kinase receptor that is encoded by the c-kit proto-oncogene. 1 It is expressed in many tissues, including hematopoietic stem cells. The ligand for this receptor is stem cell factor (also known as kit ligand, steel factor, or mast cell growth factor).
A b s t r a c t

We assessed the diagnostic usefulness of adding anti-CD117 to our existing flow cytometric profile in the analysis of 150 consecutive cases of acute leukemia (de novo or relapsed acute myelogenous leukemia [AML], AML arising in myelodysplastic syndrome, blast crisis of chronic myelogenous leukemia [CML], acute lymphoblastic leukemia, acute unclassifiable leukemia, and biphenotypic leukemia). CD117 was expressed on more than 10% of blasts in 64% of de novo AMLs (42/66), 95% of relapsed AMLs
, 75% of AMLs arising from a myelodysplastic syndrome (6/8) , and 25% of myeloid blast crisis in CMLs (1/4 CD117 (c-kit) is a transmembrane tyrosine kinase receptor that is encoded by the c-kit proto-oncogene. 1 It is expressed in many tissues, including hematopoietic stem cells. The ligand for this receptor is stem cell factor (also known as kit ligand, steel factor, or mast cell growth factor).
In normal bone marrow, approximately 2% to 4% of mononuclear cells express CD117. 2, 3 Approximately 25% of normal CD34+ cells in the bone marrow coexpress CD117. [2] [3] [4] In leukemic processes, CD117 expression is reported in more than 50% of acute myelogenous leukemias (AMLs) but is rarely seen in acute lymphoblastic leukemias. 5 Some authors have advocated the routine use of anti-CD117 in the immunophenotypic analysis of leukemias. 6 We studied the expression of CD117 in a consecutive series of acute leukemias to evaluate its sensitivity and specificity for detecting myeloid leukemic processes and to evaluate correlation, if any, between CD117 expression and the FrenchAmerican-British (FAB) subclassification. Furthermore, we sought to assess the usefulness of adding anti-CD117 to a comprehensive diagnostic evaluation that included morphologic examination of Wright-Giemsa-stained samples, cytochemical analysis, and an extensive panel of surface membrane and cytoplasmic immunophenotypic markers analyzed by flow cytometry. months to 88 years (median, 45 years) and 71% were adults (older than 18 years). Of the patients, 110 were studied at initial examination, and the remaining 40 were studied at relapse.
The series consisted of 66 cases of de novo AML (M0, 5; M1, 10; M2, 21; M3, 4; M4, 7; M5a, 2; M5b, 5; M7, 2; unclassified, 10), 20 of relapsed AML, 8 of AML arising in myelodysplastic syndrome, 4 of myeloid blast crisis of chronic myelogenous leukemia (CML), 2 of lymphoid blast crisis of CML, 20 of de novo B-precursor acute lymphoblastic leukemia (ALL), 17 of relapsed B-precursor ALL, 3 of L3 (Burkitt) ALL, 5 of de novo T-ALL, 2 of relapsed T-ALL, 1 of relapsed biphenotypic acute leukemia, and 2 of acute leukemia that could not be subclassified further. Diagnoses were established by morphologic review, cytochemical analysis, and flow cytometric analysis. AMLs were subclassified by FAB criteria when possible using cytochemical stains for myeloperoxidase and alpha-naphthyl butyrate esterase.
Flow cytometric immunophenotyping was performed by 3-and 4-color immunofluorescence staining. Samples were analyzed using an EPICS XL-MCL flow cytometer (Beckman Coulter, Miami, FL). Leukocytes from heparinized bone marrow (95 cases), peripheral blood (52 cases), or cerebrospinal fluid (3 cases) were incubated with antibody cocktails according to the manufacturer's recommendation. Monoclonal antibodies were directly conjugated with fluorescein isothiocyanate (FITC), phycoerythrin (PE), PE-cyanine 5, or PE-Texas red. The reagent panel is summarized in ❚Table 1❚. Blast gates were established with CD45 (J33) vs side scatter. Isotype-matched negative controls were used for all reagents. To be considered positive, a test marker had to label at least 20% of the blasts with a fluorescence intensity greater than the negative control (except for CD117 and cytoplasmic antigens for which an arbitrary threshold of 10% was used, similar to other reports). [6] [7] [8] Anti-CD117 (PE) was tested in 3-color combination with anti-CD45 (PE-Texas red) and anti-CD7 (FITC).
The routine acute leukemia panel used in our flow cytometry laboratory includes antibodies to CD2, CD3, CD5, CD7, CD10, CD11c, CD13, CD14, CD19, CD20, CD22, CD33, CD34, CD45, and CD56. This basic profile may be supplemented with antibodies to CD1a, CD4, CD8, CD61, kappa, and lambda as needed. Anti-cytoplasmic myeloperoxidase, CD3, and CD22 also may be used in select cases. Concurrent record of CD117 expression was obtained for each case for the duration of the study. Original diagnoses and lineage assignments were made without consideration of CD117. Once case accrual was complete, diagnoses and lineage assignments were reviewed in the context of CD117 results.
Statistical Analysis
Sensitivity of CD13, CD33, and CD117 was determined by dividing cases of myeloid lineage that were positive for the marker by the total number of cases of myeloid lineage. Specificity was found by dividing the nonmyeloid cases that were negative for the marker by the total number of nonmyeloid cases. Given that the cases were collected consecutively, we assumed that the number of cases of myeloid and nonmyeloid cases were a good estimate of the true population. Therefore, based on this assumption, the negative predictive value was calculated by dividing the nonmyeloid cases with a negative result by all cases that were negative. The positive predictive value was determined by dividing the myeloid cases with a positive value by all cases that were positive for a specific marker. The myeloid-associated markers anti-CD13, -CD33, and -CD117 were compared with each other based on calculations of sensitivity and specificity for the detection of myeloid lineage. Furthermore, calculations of positive predictive value and negative predictive value were used to compare the usefulness of CD117, CD13, and/or CD33 for discriminating acute myeloid leukemia from acute lymphoid leukemia.
Results
CD117 expression was found on more than 10% of blasts in 42 (64%) of 66 cases of de novo AML, 19 (95%) of 20 cases of relapsed AML, 6 (75%) of 8 cases of AML arising in a myelodysplastic syndrome, and 1 (25%) of 4 cases of myeloid blast crisis occurring in CML. No CD117 expression was detected in any type of ALL (0/47), acute biphenotypic or unclassifiable leukemia (0/3), or lymphoid blast crisis of CML (0/2).
Data on the frequency of CD117 expression in the various FAB subtypes of AML are listed in ❚Table 2❚. FAB AML M2 included the highest percentage of cases positive for CD117. No CD117 expression was found in 2 cases of AML M5a. No case of AML M6 was available for study. Of the relapsed cases of AML, only 1 case was studied for CD117 de novo. This case had the same expression profile of CD117 in the samples from the de novo specimen and the specimen after relapse.
CD117 was highly specific for differentiating acute myeloid from acute lymphoid leukemias. In fact, the specificity for the myeloid lineage was greater than that for CD13 and/or CD33. Despite the high level of specificity of CD117 for myeloid lineage, we found no cases in which CD117 positivity resulted in reassignment of lineage from lymphoid to myeloid. In other words, all lineage assignments established based on morphologic features, cytochemical analysis, and our standard flow cytometric panel remained unchanged after acquisition of CD117 data. In regard to sensitivity, CD13 and/or CD33 were seen more frequently in cases of AML. ❚Table 3❚ summarizes the sensitivity and specificity of CD117 compared with CD13, CD33, or both.
CD117 expression in myeloblasts generally was dim. The mean fluorescence intensity was uniformly within the first decade log in all but one of the positive cases (1/68), despite the use of a PE conjugate.
Discussion
CD117 is a specific marker for AML arising de novo or in association with myelodysplastic syndromes. Overall, we found CD117 expression in 69% of myeloid leukemic processes (AML, MDS-AML, and CML myeloid blast crisis). Others have reported CD117 expression by flow cytometric analysis in 23% to 91% of AML cases. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Our findings are in agreement with the largest studies that found CD117 in 63% to 67% of AML cases. [9] [10] [11] We found no CD117 expression in ALL. Other studies have found rare examples of expression in ALL, more frequently those of T-lineage than of B-lineage. 6,10-14 Our study included 7 cases of T-ALL. Although the number of cases of T-ALL studied was small, one should consider the possibility that the anti-CD117 clone might account for a difference in specificity. Notably, studies that reported positive staining in occasional T-ALL used the antibody clones LC-KIT (Lander Diagnostico, Madrid, Spain) 6 and YB5.B8 (Immunotech, Marseille, France). 10, 11, 13, 14 In studies of messenger RNA (mRNA) expression, Nishii et al 21 found c-kit mRNA in 4 of 12 cases of T-ALL. However, Wang et al 22 found no c-kit mRNA in 3 cases of T-ALL studied, and Lerner and colleagues 23 also found no c-kit mRNA in 1 case of T-ALL. Although CD117 has a high specificity, it is not as sensitive as CD13 or CD33 for detecting myeloid leukemic processes. Approximately 30% of acute myeloid leukemia did not stain with anti-CD117. Although 99% of acute myeloid leukemias were positive for CD13 and/or CD33 in our series, the myeloid specificity of CD13 and/or CD33 is much lower than that of CD117. However, through careful morphologic review and the use of a comprehensive immunophenotyping panel and cytochemical stains, we found that myeloid lineage assignment could be established in all instances without the use of CD117. Furthermore, according to the findings in a German cooperative study 9 and the Children's Cancer Group, 17 CD117 status seems to lack prognostic significance in AML.
CD117 expression does not seem to be a reliable predictor of FAB AML subtype. In the present study, the highest frequency of CD117 expression was found in the AML M2 category (90% positive). In addition, 80% of cases in the AML M0 group had CD117 expression. In contrast, we found no CD117 in AML M5a, and only 20% of cases of M5b expressed this antigen. The total number of M5 cases in our study was small, however, precluding firm conclusions. Previous studies have reported a range of CD117 expression in AML M5 varying from 0% to 69%. [6] [7] [8] [9] [10] [11] [12] [13] [14] 19, 20, 23 The 2 largest series documented CD117 expression in 21.2% 9 and 32.8% 10 of AML M5. Few studies have specifically compared M5a with M5b with regard to CD117 protein expression 6, 7 or mRNA expression 23 ; these studies indicate that CD117 expression occurs frequently in M5a but is unusual in M5b.
The surface antigen density of CD117 is generally low in AML, as the fluorescence intensity is typically dim by flow cytometric methods. This may account, in part, for the broad range of reported CD117 expression in acute myeloid leukemias. In the present study, only 1 of the 68 positive cases had a mean fluorescence intensity greater than 1 decade log above the negative control. To optimize detection sensitivity in these circumstances, a PE conjugate is preferable to an FITC conjugate of the antibody.
Anti-CD117 (clone 95C3) seems to be a specific marker for myeloid lineage in acute leukemia. However, addition of this marker to our routine acute leukemia immunophenotyping panel added no significant diagnostic benefit. It may be a useful adjunct in difficult cases, but it does not seem to add much in the usual case of acute leukemia. Others using a different anti-CD117 clone, YB5.B8, have drawn similar conclusions. 13 
